• 1
    Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56( Suppl 1): S88S100.
  • 2
    Hawke RL, Schrieber SJ, Soule TA, Wen Z, Smith PC, Reddy KR, et al. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol 2010; 50: 434449.
  • 3
    Beinhardt S, Rasoul-Rockenschaub S, Scherzer TM, Ferenci P. Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C. J Hepatol 2011; 54: 591592.
  • 4
    Neumann UP, Biermer M, Eurich D, Neuhaus P, Berg T. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J Hepatol 2010; 52: 951952.
  • 5
    Eurich D, Bahra M, Berg T, Boas-Knoop S, Biermer M, Neuhaus R, et al. Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy. Exp Clin Transplant 2011; 9: 16.
  • 6
    Rutter K, Scherzer TM, Beinhardt S, Kerschner H, Stattermayer AF, Hofer H, et al. Intravenous silibinin as ‘rescue treatment’ for on-treatment non-responders to pegylated interferon/ribavirin combination therapy. Antivir Ther 2011; 16: 13271333.
  • 7
    Payer BA, Reiberger T, Rutter K, Beinhardt S, Staettermayer AF, Peck-Radosavljevic M, et al. Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient. J Clin Virol 2010; 49: 131133.
  • 8
    Biermer M, Berg T. Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin. Gastroenterology 2009; 137: 390391.
  • 9
    Biermer M, Schlosser B, Fulop B, van Bommel F, Brodzinski A, Heyne R, et al. High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy. J Viral Hepat 2012; 19: 547553.
  • 10
    Ahmed-Belkacem A, Ahnou N, Barbotte L, Wychowski C, Pallier C, Brillet R, et al. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology 2010; 138: 11121122.
  • 11
    Wagoner J, Morishima C, Graf TN, Oberlies NH, Teissier E, Pecheur EI, et al. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PLoS One 2011; 6: e16464.
  • 12
    Binder M, Quinkert D, Bochkarova O, Klein R, Kezmic N, Bartenschlager R, et al. Identification of determinants involved in initiation of hepatitis C virus RNA synthesis by using intergenotypic replicase chimeras. J Virol 2007; 81: 52705283.
  • 13
    Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, et al. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 2011; 9: 3245.
  • 14
    Gouttenoire J, Penin F, Moradpour D. Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory. Rev Med Virol 2010; 20: 117129.
  • 15
    Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008; 135: 15611567.
  • 16
    Yi M, Lemon SM. Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells. J Virol 2004; 78: 79047915.
  • 17
    Lohmann V, Körner F, Koch JO, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110113.
  • 18
    Gosert R, Egger D, Lohmann V, Bartenschlager R, Blum HE, Bienz K, et al. Identification of the hepatitis C virus RNA replication complex in huh-7 cells harboring subgenomic replicons. J Virol 2003; 77: 54875492.
  • 19
    Gouttenoire J, Montserret R, Kennel A, Penin F, Moradpour D. An amphipathic alpha-helix at the C terminus of hepatitis C virus nonstructural protein 4B mediates membrane association. J Virol 2009; 83: 1137811384.
  • 20
    Paul D, Romero-Brey I, Gouttenoire J, Stoitsova S, Krijnse-Locker J, Moradpour D, et al. NS4B self-interaction through conserved C-terminal elements is required for the establishment of functional hepatitis C virus replication complexes. J Virol 2011; 85: 69636976.
  • 21
    Gouttenoire J, Roingeard P, Penin F, Moradpour D. Amphipathic alpha-helix AH2 is a major determinant for the oligomerization of hepatitis C virus nonstructural protein 4B. J Virol 2010; 84: 1252912537.
  • 22
    Egger D, Wolk B, Gosert R, Bianchi L, Blum HE, Moradpour D, et al. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 2002; 76: 59745984.
  • 23
    Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DY, Liu Y, et al. Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci U S A 2010; 107: 59955999.
  • 24
    Paredes AM, Blight KJ. A genetic interaction between hepatitis C virus NS4B and NS3 is important for RNA replication. J Virol 2008; 82: 1067110683.
  • 25
    Wesolowska O, Lania-Pietrzak B, Kuzdzal M, Stanczak K, Mosiadz D, Dobryszycki P, et al. Influence of silybin on biophysical properties of phospholipid bilayers. Acta Pharmacol Sin 2007; 28: 296306.
  • 26
    Dvory-Sobol H, Pang PS, Glenn JS. The future of HCV therapy: NS4B as an antiviral target. Viruses 2010; 2: 24812492.
  • 27
    Barcena R, Moreno A, Rodriguez-Gandia MA, Albillos A, Arocena C, Blesa C, et al. Safety and anti-HCV effect of prolonged intravenous silibinin in HCV-genotype 1 subjects in the immediate liver transplant period. J Hepatol 2012 [Epub ahead of print].
  • 28
    Marino Z, Crespo G, D'Amato M, Brambilla N, Giacovelli G, Rovati L, et al. Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period. J Hepatol 2012 [Epub ahead of print].
  • 29
    Aghemo A, Bhoori S, De Nicola S, Mazzaferro V, Colombo M. Failure of intravenous silibinin monotherapy to prevent hepatitis C genotype 2A liver graft reinfection. Hepat Mon 2012; 12: 411414.